Why the study?
Alzheimers disease pathophysiology remains incompletely elucidated with no disease-halting treatments, prompting exploration of renin-angiotensin system interactions with neuroinflammation and cerebrovascular regulation.
Do RAS-targeting drugs like ACE inhibitors and ARBs provide therapeutic benefits in Alzheimer's Disease?
Do RAS-targeting drugs like ACE inhibitors and ARBs provide therapeutic benefits in Alzheimer's Disease?
The brain renin-angiotensin system interacts with Alzheimer's disease pathophysiology, suggesting a potential therapeutic role for ACE inhibitors and ARBs.
No takes yet. Share an insight, caveat, or question.
Brain RAS interactions with AD pathology suggest potential targets; leaves open whether RAS modulation alters clinical progression.
Ribeiro et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: